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While the Cysteine-Rich Secretory Proteins (CRISPs) have been broadly proposed as regulators of
reproduction and immunity, physiological roles have yet to be established for individual members of this
family. Past efforts to investigate their functions have been limited by the difficulty of purifying correctly
folded CRISPs from bacterial expression systems, which yield low quantities of correctly folded protein
containing the eight disulfide bonds that define the CRISP family. Here we report the expression and
purification of native, glycosylatedCRISP3 fromhuman andmouse, expressed inHEK293 cells and isolated
using ion exchange and size exclusion chromatography. Functional authenticity was verified by
substrate-affinity, native glycosylation characteristics and quaternary structure (monomer in solution).
Validated protein was used in comparative structure/function studies to characterise sites and patterns of
N-glycosylation in CRISP3, revealing interesting inter-species differences.
E
xpression of the Cysteine-Rich Secretory Proteins (CRISPs) occurs primarily in the male reproductive
tissues and salivary glands; in mammals, expression is biased to the reproductive tract, while in many
poisonous non-mammalian vertebrates such as snakes and lizards, CRISPs are secreted into venom where
they exert toxicity through ion channel inhibition1–5. The mechanisms by which CRISPs function in the mam-
malian reproductive tract are less clear, however individual roles in the processes of decapacitation, acrosome
reaction, sperm-oocyte fusion, flagellar motility and immunosuppression have recently been proposed6–14. The
latter function has been attributed to equine CRISP3, which is present in high concentrations in seminal plasma
and has been shown to inhibit sperm-neutrophil interaction in horses14. Whether this function of equine CRISP3
extends to its mouse and human orthologs remains to be determined.
Structurally, CRISPs constitute one of eleven mammalian subfamilies of the CAP (CRISP, Antigen 5 and
Pathogenesis-Related 1 proteins) superfamily, to which they belong by virtue of their N-terminal CAP domain2.
They are characterised by the presence of a C-terminal CRISP domain, a collective term encompassing an ion
channel regulator (ICR) domain and the ‘hinge’ which links the ICR and CAP domains (Figure 1). As its name
suggests, the CRISP domain comprises an unusually cysteine-rich sequence in which ten cysteine residues form
five disulfide bonds; the CAP domain of the protein encodes a further six cysteine residues which are also
exclusively disulfide bonded2,15. These eight disulfide bonds confer to CRISPs their high degree of structural
complexity. Unsurprisingly therefore, recombinant expression of functional CRISPs has proven difficult, with a
number of previous attempts resulting in the production of misfolded, insoluble protein aggregates by bacterial
systems; this material must then be subjected to an involved and often inefficient refolding process12,13,16. This,
along with the problem of often inadequate post-translational modification of mammalian proteins by bacteria,
creates a need for an improved approach to CRISP expression and purification.
Here we used a mammalian protein expression system to generate useful quantities of soluble, correctly folded
and post-translationally modified human CRISP3, as validated by interaction with the known serum binding
partner alpha-1-B glycoprotein17,18.We also show that this validated CRISP3 preparation can provide informative
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Results
Expression of soluble human CRISP3. Stable, inducible HEK 293
cell lines expressing human or mouse CRISP3 were generated.
Following 96–120 hours of induction, human His-tagged CRISP3
constituted approximately 1.8% of total protein in the cell media
(1.5 mg/ml by comparison with a CRISP3 standard). Protein
stability and lack of toxicity was indicated by a proportional
increase in CRISP3 concentration with induction time (Figure 2A).
Deglycosylase treatment with Peptide -N-Glycosidase F (PNGase F)
confirmed that like native CRISP3, the recombinant protein was
secreted in unglycosylated and N-glycosylated forms (Figure 2B)19.
Purification and validation of human CRISP3.We found that the
nickel/cobalt coated resins used for His-tag purification lacked
specificity with conditioned HEK cell medium, such that many
secreted proteins bound to the column despite optimisation
attempts. As an alternative enrichment method, we employed
carboxymethyl (CM) cellulose cation exchange to achieve a fifteen-
fold purification and 75% recovery. Subsequent size-exclusion
chromatography achieved a further 2.5-fold enrichment with near-
quantitative recovery and 67% purity (Figure 3B and Table 1).
Immunoreactivity, SDS-PAGE analysis and glycosylation profile
data were supported by mass spectrometry analysis of tryptic
peptides from the predominant 26-kDa bands, which confirmed
their identity as mouse and human CRISP3 (three high-quality
sequence tags for each, not shown).
A single major contaminating protein in both human and mouse
preparations was identified bymass spectrometry as alpha-enolase, a
48 kDa glycolytic enzyme, with a Mascot score of 159 (6 peptides,
19% sequence coverage). Secreted alpha enolase binds CM
cellulose20–24.
Recombinant human CRISP3 binds A1BG. In the absence of a
standard CRISP3 activity assay, we tested the ability of purified
human CRISP3 to perform its only reported biological function,
that of binding the serum protein alpha-1-B glycoprotein (A1BG),
itself a protein of uncertain function17,18. Silver staining of CRISP3-
binding human and bovine serum proteins revealed bands
corresponding to A1BG in CRISP3-treated samples but not in
untreated controls (Figure 4A). Mass spectrometry analysis
confirmed their identity as human and bovine A1BG with Mascot
scores of 343 (10 peptides, 26% sequence coverage) and 170 (4
peptides, 12% sequence coverage) respectively. Reduction and
alkylation of recombinant CRISP3 practically abolished the
CRISP3-A1BG interaction, indicating that the recombinant protein
contains tertiary structure elements required for A1BG recognition
(Figure 4B).
Identification ofmouse and humanCRISP3N-glycosylation sites.
Purification of mouse CRISP3 (Figure 3C) revealed that its putative
glycosylated form possessed lower electrophoretic mobility than
glycosylated human CRISP3 (Figure 5A). To identify the site(s) of
N-glycosylation in mouse CRISP3, site-directed mutagenesis was
performed at three NXS/T motifs; N99, N113 and N156, where
amino acid number reflects post-cleavage position. These were
mutated individually and in combination to produce the mutants
N99Q, N113Q, N156Q, N99Q 1 N113Q and N99Q 1 N113Q 1
N156Q. Western blot analysis showed that N99Q and N113Q (but
not N156Q) mutations affected protein size, indicating glycosylation
at both sites in the wild type protein (Figure 5B, C). Interestingly, we
observed that twomutants (N99Q1N113Q andN99Q1N113Q1
N156Q) incapable of undergoing glycosylation were of relatively low
abundance in the cell media (Figure 5C).
N-glycosylation of human CRISP3 at N220 only was confirmed,
with no observable glycosylation of hCRISP3-N220Q (Figure 6B, last
lane), and no impairment in protein secretion.
Partial characterisation of mouse CRISP3 N-glycosylation types.
To investigate the nature of mouse CRISP3 glycosylation, the N99Q
and N113Q mutants were exposed to the deglycosylase Endoglyco-
sidase H (Endo H). Endo H leaves complex oligosaccharides intact
while cleaving high mannose and some hybrid N-linked oligosa-
ccharides. Under standard reaction conditions, partial digestion of
the mouse wild type, N99Q and N113Q proteins was observed
following Endo H treatment (Figure 6A); none of a range of time
and temperature conditions employed improved sensitivity to the
enzyme. Human CRISP3 was resistant to Endo H, as expected19.
Western blot comparison of mouse and human glycans revealed a
size difference consistent with complex and high mannose
modifications respectively (Figure 6B, lanes 1 and 2).
Finally, in a comparison of the relative mobility of salivary gland
CRISP3 with three post-translationally modified variants of the
recombinant protein, only the unglycosylated form of mouse
CRISP3 could be observed in whole salivary gland (Figure 7).
Figure 1 | CRISP domain organisation and tertiary structure. (A) CRISP
domain organisation and (B) homology models of mouse and human
CRISP3 based on the crystal structure of Natrin. The CRISP domain is
shown in blue/aqua; disulfide bonds by white/yellow linkages. N-
glycosylation is represented by high mannose (mouse CRISP3) and
complex (human CRISP3) glycans (ball and stick models).
Figure 2 | HEK 293 cells efficiently secrete unglycosylated and N-
glycosylated recombinant human CRISP3. (A) Western blot with human
CRISP3 antibody showing CRISP3 induction. (B) PNGase F treatment
selectively affects the larger CRISP3 variant in both native (human seminal
plasma, first two lanes) and recombinant (‘rCRISP3-His’, last two lanes)
protein. Full length gels are available under supplementary data.
www.nature.com/scientificreports
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Discussion
The structural complexity conferred by the high cysteine content of
CRISPs has repeatedly caused purification attempts from bacterial
cells to result in the production of insoluble inclusion bodies even
under conditions intended to favour disulfide bond formation12,13.
Alternative purification methods from neutrophil extracts have
employed cation exchange and affinity chromatography, but these
approaches are limited by tissue availability18,19. Here we dem-
onstrate that recombinant human CRISP3 expression and two-step
purification from HEK 293 cells yields milligram quantities of sol-
uble protein suitable for structure/functional analyses. Indications of
functional authenticity included efficient secretion, post-trans-
lational modification and confirmed interaction with the known
binding partner A1BG, which was abolished with denaturation of
CRISP3. The recombinant protein reproduced the native CRISP3
glycosylation profile, with site-directed mutagenesis confirming
N220 as the exclusive site of N-glycosylation. A published report
of Endo H resistance suggesting a hybrid or complex carbohydrate
modification was confirmed19.
We present the first report of mouse CRISP3 immunodetection by
western blotting using amouse CRISP3-specific antibody of our own
production, as well as the first evidence of N-glycosylation at two
sites (N99 andN113).While incomplete digestion by EndoH of both
glycosylation sites may reflect either imperfect enzyme access to
cleavage sites or a mixture of glycosylation types, both N99 and
N113 likely represent sites of high mannose or hybrid glycosylation
to some degree. A relationship between glycosylation state and pro-
tein function (affecting protein stability or intracellular retention)
was suggested by the relatively low abundance of unglycosylated
mouse CRISP3. We speculate that glycosylation of mouse, but not
human CRISP3, is required for escape from the ER quality control
system25.
A gel comparison of salivary gland CRISP3 to three post-transla-
tionally modified variants of the recombinant protein indicated that
Figure 3 | CRISP3 is enriched 15-fold following CM cellulose exchange. (A) Silver-staining at various purification stages. Lane 1: starting material
(250 ml conditioned media), lane 2: CM cellulose flow through, lanes 3–10: CM cellulose exchange gradient elutions (CRISP3 elutes in lanes 7–8,
representing 110 and 240 mM NaCl respectively). (B) CRISP3 gel filtration to over 60% purity. (C) Mouse CRISP3 purified by the same method (two
bands, 26 and 33 kDa). The 48 kDa contaminant is alpha-enolase. (D) Gel filtration absorbance trace with human CRISP3 peak indicated by the arrow.
All gels were run under the same conditions.
Table 1 | CRISP3 purification from HEK 293 conditioned media
Step Volume (ml) Protein (mg)* hCRISP3 (mg){ Purification (fold) Recovery (%)
1. Media 500 40 720 1 100
2. CM cellulose 10 2.2 540 15 75
3. S75 10 0.75 500 37 70
*Determined by Bradford assay.
{Determined by western blot comparison with commercial HIS-tagged CRISP3 standard and densitometry of silver-stained SDS PAGE (steps 1 and 2–3 respectively).
www.nature.com/scientificreports
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in whole salivary gland at least, mouse CRISP3 is wholly or predo-
minantly unglycosylated. Clarification of glycosylation patterns in
other tissues is required; as we have demonstrated a link between
glycosylation and secretion efficiency, it will be of particular interest
to compare the glycosylation profile of CRISP3 from whole tissues
with that obtained from endocrine secretions. Finally, we note that
while human CRISP3 is glycosylated in the CRISP domain only
(N220), both mouse glycosylation sites N99 and N113 are found in
the N-terminal CAP domain (Figure 1B); this difference in glycosy-
lation pattern may indicate distinct functions. This glycosylation site
distribution appears to reflect a broader species-specific pattern in
which human CRISPs 1 and 3 are N-glycosylated in the ICR domain
with no N-glycosylation motifs in the CAP domain, while all four
mouse CRISPs have potential N-glycosylation sites in their CAP but
not CRISP domains. The major form of seminal plasma human
CRISP1 contains a 4 kDa glycan, consistent with complex modifica-
tion26. N-glycosylation motif sequences are absent in human CRISP2
and equine CRISP3, to which a neutrophil-suppressive function has
been attributed14.
Sequence differences between pseudechetoxin and pseudecin, two
cyclic nucleotide-gated ion channel blocking venom CRISPs with a
15–30-fold difference in affinity, suggest that most of the critical
functional residues responsible for contact with target ion channels
are concentrated on the concave surface of the proteins spanning the
CAP-CRISP domain interface27,28. That this cleft formed by the
bridge between CRISP and CAP domains is involved in substrate
binding is supported by evidence that the ICR domain of CRISPs
alone provides inadequate or suboptimal ion-channel inhibition, so
that the CAP domain is believed to provide additional specificity to
the ion channel interaction12,28. Indeed, sequence homology studies
have identified a collection of residues within snake venom CRISPs
which form a continuous line along the protein backbone and have
been subject to high frequency evolutionary variation29. Sequence
variability in these regions is therefore likely to confer selectivity
Figure 4 | Recombinant humanCRISP3 binds human and bovineA1BG. (A)Gel analysis of proteins purified on recombinant CRISP3-coated cyanogen
bromide resin showedCRISP3 interactionwith A1BG fromboth human (lane 3,,85 kDa band) and bovine (lane 3,,65 kDa band) serum, as confirmed
by mass spectrometry. Elution control samples were loaded as follows; lane 1: uncoated beads incubated with serum, lane 2: CRISP3-coated beads
incubated with PBS, lane 3: CRISP3-coated beads incubated with serum. In the case of human serum, all eluted proteins in lane 3 other than A1BG bound
non-specifically to the beads (compare with lane 1). (B) Denatured CRISP3 (lane 3) was unable to bind A1BG. Full length gels are available under
supplementary data; gels were run under the same conditions.
Figure 5 | RecombinantmouseCRISP3 is glycosylated atN99 andN113.Western blotting withHis tag antibody showed glycosylated human andmouse
CRISP3-His to be 29 and 33 kDa respectively (A). (B) Peptide pre-absorption of mouse CRISP3 antibody. (C)Mouse CRISP3 N99Q andN113Qmutant
proteins were smaller than wild type (WT) mouse CRISP3 (PNGase F untreated samples); N156Q was unaffected. Two mutants unable to undergo
glycosylation (N99Q1N113Q and N99Q1N113Q1N156Q) were of relatively low abundance. ‘NT’ represents non-transfected HEK cell media. Full
length gels are available under supplementary data; gels were run under the same conditions.
www.nature.com/scientificreports
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and affinity for binding partners, accounting for the diverse range of
CRISP ion channel targets. A comparison of CRISP and CAP pro-
teins from multiple species similarly identified three hypervariable
regions in the CAPdomainwhichwere postulated to confer substrate
specificity30. The mouse CRISP3 glycosylation site N113 lies within
one of these hypervariable regions, corresponding to G109-V117, in
the CAP domain. Due to the high degree of rotational freedom of the
CAP and ICR domains and the lack of an ICR domain in many CAP
proteins, a separate, non-ion channel binding function has often
been postulated for the CAP domain. If the G109-V117 sequence
confers specificity to either an ion-channel interaction or distinct
CAP domain function, then carbohydrate addition within this region
may have significant functional implications. 25 and 12 amino acids
separate the critical 5-amino acid variable ion-channel binding
sequence in the ICR domain from the human CRISP3 and CRISP1
N-glycosylation sites, respectively. Despite the addition of a large,
complex sugarmoiety in close proximity to the CRISP3 binding cleft,
Udby et al. have previously shown that interaction with at least one
binding partner, A1BG, occurs independently of CRISP3 glycosyla-
tion status18.
In conclusion, this study describes a new method of producing
CRISP3 of sufficient abundance and purity for structure/function
analysis, as demonstrated by elucidation of the sites of glycosylation
of mouse CRISP3, about which very little is currently known.
Methods
Cloning, transfection and cell culture. Human and mouse CRISP3 cDNA were
amplified from total RNA extracts of the LNCaP prostate cancer cell line and wild
type C57BL/6 mouse salivary gland respectively. cDNAs were cloned following
addition of attB sites by PCR using the Gateway system (Life Technologies), and the
pcDNA5/FRT/TO-CRISP3 product obtained. AttB primers used for human CRISP3
were: forward primer 59ggggacaagtttgtacaaaaaagcaggcttcttcaccatgacattattcccagt-
gctgttg, reverse primer 59ggggaccactttgtacaagaaagctgggtcttaataaatgctgtttgaacaattgc.
For mouse CRISP3, the primers used were: forward primer 59 ggggacaagtttgtacaaaa-
aagcaggcttcttcaccatggcattaatgcttgtg, reverse primer 59 ggggaccactttgtacaagaaagct-
gggtcttaacattggcatgtagc. The QuickChange Lightning Site-Directed Mutagenesis kit
(Stratagene) was used to introduce N-terminal 6xHis tags to human and mouse
CRISP3 following the third post-cleavage amino acid. For human CRISP3, these
primers were: forward primer 59catcatcaccatcaccacgcaaatgaagataaggatcccgctt-
ttactgctttg, reverse primer 59 ttcatttgcgtggtgatggtgatgatgttcatttgctggaaaagatggaagcag.
Mouse His tag primers were: forward primer: 59 caagataaccatcatcaccatcaccaccaaga-
taactctcaggagaacagtcttgag, reverse primer 59 gttatcttggtggtgatggtgatgatggttatcttgaa-
gaagggatggggg. Glycosylation site mutants contained the following amino acid
changes: N99Q, N113Q, N156Q, N99Q 1 N113Q, N99Q 1 N113Q 1 N156Q
(mouse CRISP3) and N220Q (human CRISP3).
Stable transfections were performed by co-transfection of CRISP3 and Flp-
recombinase (pOG44) expression vectors into FlpIn T-Rex HEK 293 cells (Life
Technologies) using FuGENEHD. Transfected cells were selected and maintained in
DMEM containing 10% FBS and 100 mg/ml hygromycin.
Expression and purification of human and mouse CRISP3. Transfected HEK cells
were grown in 175 cm2 flasks until confluent, when culture media was removed and
cells washed twice with PBS. Protein expression was induced for 96–120 hours in
FBS-free DMEM containing 1 mg/ml tetracycline. Media was cleared with a 0.2
micron filter and supplemented with 1 mM PMSF upon collection.
Conditioned media was concentrated 4-fold with 10 kDa Amicon Ultra-15
Centrifugal Filter Units (Millipore). Concentrate was diluted with 7 volumes of
binding buffer (10 mMHEPES, pH 6.5) to reduce NaCl concentration from 160 mM
to 20 mM, and the pH adjusted to 6.5 with 1 M HCl. CM cellulose (Sigma-Aldrich),
previously washed according to instructions and resuspended in dH2O, was adjusted
to pH 6.5 and added as a 50% slurry to the protein solution to a 1% final volume. This
mixture was incubated at 4uC for 1 hour with gentle rotation. Unbound protein was
removed through a sintered glass funnel under vacuum, the resin washed twice with
10 times the resin volume of binding buffer, and adjusted to a 50% slurry. This was
packed into a 13 50 cmEcono-Column (BioRad) column and washed until the resin
bed was compact. The following gradient elution program was carried out at a flow
rate of 1 ml/minute; 5 minute wash, 30 minute gradient elution of 0–1 M NaCl in
wash buffer, 5 minute wash with 1 M NaCl in wash buffer, 5 minute wash with wash
buffer.
Gel filtration was performed on a Hi Load 16/60 Superdex 75 column (GE
Healthcare Life Sciences). Samples were diluted in PBS and 1 ml fractions were
collected at 1.2 ml per minute at 4uC. CRISP3-containing fractions were identified by
immunoblotting and correlated with the absorbance trace.
Deglycosylase treatment. Human or mouse pcDNA5/FRT/TO-CRISP3 constructs
were transiently transfected into HEK T-Rex cells as described. Protein expression
was induced 24 hours after transfection and media collected 48 hours later. For both
control and PNGase F/Endo H (New England Biolabs) treatments, 1 ml mediumwas
concentrated to 20 ml with a 10 kDa Amicon Ultra-4 Centrifugal Filter Unit
(Millipore) and samples were treated with deglycosylase buffers according to
instructions; in control treatments, dH2O was substituted for enzyme. Samples were
treated for 3 hours at 37uC before addition of Laemmli buffer.
Anti-mouse CRISP3 antibody production and validation. A mouse CRISP3-
specific antibody was raised in goats against the peptide QYKDMSFWCKRLEYVC
conjugated to diphtheria toxoid (Antibodies Australia, Clayton, VIC) and purified
using a peptide affinity column as described previously31,32. 1 mg/ml was used for
western blotting, with specificity validated by pre-absorption with 150-fold molar
excess of immunising peptide (16 hour incubation at 4uC).
Western blotting. Conditioned medium was concentrated with an Amicon
Centrifugal Filter Unit and boiled for 10 minutes in Laemmli buffer (2% b-
mercaptoethanol). Proteins were separated on precast 4–15% acrylamide Criterion
Tris/HCl SDS-PAGE gels (Bio-Rad) for 2.5 hours at 110 V. Transfers were perfomed
at 4uC for 55minutes at 100 V onto nitrocellulosemembrane and blocked in 5% skim
milk powder/TBS-T (0.05% Tween-20) for one hour at room temperature. Human
CRISP3 antibody (R&D Systems, MAB23971) was used at 2.5 mg/ml in blocking
buffer for one hour at room temperature. His-tag antibody (Cell Signalling
Technology, 2366) was used at a 151000 dilution. Li-cor secondary antibodies were
diluted 500-fold in blocking buffer and imaging performed on the Odyssey Infrared
Imaging System (Li-cor Biosciences).
A1BG binding. A1BG binding was carried out using cyanogen bromide-activated-
Sepharose 4B (Sigma Aldrich) essentially as described by Udby et al17. 50 mg purified
human CRISP3 was used per treatment with 0.5 ml FBS or 0.1 ml human serum.
Denatured CRISP3 was obtained by reduction with 20 mM DTT for 1 hour at 55uC
followed by addition of iodoacetamide for 1 hour at room temperature in the dark.
Buffer exchange to PBS was performed with a10 kDa Amicon Ultra-15 Centrifugal
Filter Unit.
Mass spectrometry.Purified and silver stained human andmouse CRISP3 from SDS-
PAGE were excised and subjected to in-gel trypsinolysis essentially as before33. Bands
Figure 6 | Mouse CRISP3 is incompletely digested by EndoH. (A)Mouse
CRISP3 wild type, N99Q and N113Q are partially digested by Endo H (E).
Complete digestionwith PNGase F (P) is included for size comparison. (B)
A size comparison ofmouse and humanCRISP3 (mCRISP3 and hCRISP3,
respectively) glycans (square brackets). Full length gels are available under
supplementary data; gels were run under the same conditions.
Figure 7 | CRISP3 from whole mouse salivary gland is unglycosylated.
Western blot comparison of wild type salivary gland CRISP3 with
recombinant mouse CRISP3 glycosylated at two sites (wild type, lane 1),
one site (N99Q, lane 2) and unglycosylated (N99Q 1 N113Q 1 N156Q,
lane 3). Full length gel is available under supplementary data.
www.nature.com/scientificreports
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were reduced (2.5 mMDTT, 30minutes, 60uC), alkylated (10 mM iodoacetamide, 30
minutes, room temperature in the dark), and digested (0.5 mg trypsin, 20 mM
ammonium bicarbonate, 37uC for 14 hours). Tryptic peptides were analysed by LC-
MS/MS using an HCT ULTRA ion trap mass spectrometer (Bruker Daltonics,
Bremen, Germany) coupled to a nano HPLC (Ultimate 3000, Dionex Corporation,
SunnyBrook, CA, USA), largely as done previously34. Identity searches were
conducted using theMASCOTMS/MS Ions Search engine (www.matrixscience.com)
against the NCBInr and Swiss-Prot databases with mammalian taxonomy selected.
Search parameters were; fixed modifications, carbamidomethyl; variable
modifications, oxidation (Met), up to one missed cleavage allowed.
Preparation of human tissues. The collection and use of tissues described in this
study was approved by the Human Research and Ethics Committee of Southern
Health (Monash Medical Centre, Monash Day Surgery and Monash University).
Human seminal plasma was obtained with informed consent from Monash IVF
(Clayton, Australia) and prepared for western blotting as described elsewhere35.
Human blood was provided with informed consent by the Monash Medical Centre
(Clayton Australia).
Preparation of mouse tissues. Animal procedures were performed in accordance
with the Australian NHMRC Guidelines on Ethics in Animal Experimentation and
approved by the Monash University Animal Experimentation Ethics Committees.
Whole mouse salivary gland was obtained from 12 week old C57BL/6 mice, frozen in
liquid nitrogen, powdered with a mortar and pestle and resuspended in tissue lysis
buffer (1% SDS, 50 mMTris, 150 mMNaCl, 1% Triton-X, pH8) containing protease
inhibitors (Calbiochem, 539134). Samples were centrifuged at maximum speed (20
minutes, 4uC) and 100 mg of protein was prepared for western blotting.
Homology modelling. A mouse CRISP3 homology model based on the crystal
structure template of Natrin, a snake venom CRISP from Taiwan Cobra (pdb 1XTA),
was generated using the prime module from the Schrodinger molecular modelling
software suite with missing residues added (Prime version 3.0 Schro¨dinger, Inc, New
York, NY 2010). The model was further refined and visualized with VMD software36.
A 50 nanosecond NAMD molecular dynamics simulation of the CRISP model was
produced. Temperature was controlled using Langevin dynamics37. The representative
glycan groups modelled were complex (tetraantennary with terminal sialic acid
residues) and highmannose (mannose-9) for human andmouse CRISP3, respectively.
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